Marc J van de Vijver

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Molecular tests as prognostic factors in breast cancer
    Marc J van de Vijver
    Department of Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Virchows Arch 464:283-91. 2014
  2. pmc Functional characterization of the 19q12 amplicon in grade III breast cancers
    Rachael Natrajan
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 14:R53. 2012
  3. pmc BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
    Henne Holstege
    Division of Molecular Biology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    BMC Cancer 10:654. 2010
  4. doi request reprint The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
    Michael Knauer
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands
    Breast Cancer Res Treat 120:655-61. 2010
  5. doi request reprint Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer
    Paul Roepman
    Agendia BV, Academic Medical Centre, Amsterdam, The Netherlands
    Clin Cancer Res 15:7003-11. 2009
  6. doi request reprint Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 15:4181-90. 2009
  7. ncbi request reprint Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
    Jolien M Bueno-de-Mesquita
    Department of Pathology, Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Lancet Oncol 8:1079-87. 2007
  8. doi request reprint Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity
    Dimitry S A Nuyten
    Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Semin Radiat Oncol 18:105-14. 2008
  9. doi request reprint Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients
    Hugo M Horlings
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 16:651-63. 2010
  10. doi request reprint Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics
    Valesca P Retel
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Technol Assess Health Care 25:73-83. 2009

Collaborators

Detail Information

Publications35

  1. doi request reprint Molecular tests as prognostic factors in breast cancer
    Marc J van de Vijver
    Department of Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Virchows Arch 464:283-91. 2014
    ..The most important aspects of the currently used tissue-based prognostic and predictive tests and the research in this area are reviewed...
  2. pmc Functional characterization of the 19q12 amplicon in grade III breast cancers
    Rachael Natrajan
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 14:R53. 2012
    ..The aim of this study was to identify the genes within the 19q12 amplicon whose expression is required for the survival of cancer cells harbouring their amplification...
  3. pmc BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
    Henne Holstege
    Division of Molecular Biology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    BMC Cancer 10:654. 2010
    ..Molecular similarities between BLBCs and BRCA1-mutated tumors may therefore provide predictive markers for therapeutic response of BLBCs...
  4. doi request reprint The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
    Michael Knauer
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands
    Breast Cancer Res Treat 120:655-61. 2010
    ..This benefit was not significant in low risk patients, who were at such low risk for recurrence and cancer-related death, that adding CT does not appear to be clinically meaningful...
  5. doi request reprint Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer
    Paul Roepman
    Agendia BV, Academic Medical Centre, Amsterdam, The Netherlands
    Clin Cancer Res 15:7003-11. 2009
    ..Here, we investigated the association of microarray-based mRNA expression levels compared with immunohistochemistry...
  6. doi request reprint Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 15:4181-90. 2009
    ..Several clinical risk factors are associated with local recurrence (LR) after BCT but are unable to explain all instances of LR after BCT. Here, gene expression microarrays are used to identify novel risk factors for LR after BCT...
  7. ncbi request reprint Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
    Jolien M Bueno-de-Mesquita
    Department of Pathology, Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Lancet Oncol 8:1079-87. 2007
    ....
  8. doi request reprint Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity
    Dimitry S A Nuyten
    Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Semin Radiat Oncol 18:105-14. 2008
    ....
  9. doi request reprint Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients
    Hugo M Horlings
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 16:651-63. 2010
    ..Specific genomic alterations, such as copy number alterations, are an important factor in tumor development and progression and are also associated with changes in gene expression...
  10. doi request reprint Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics
    Valesca P Retel
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Int J Technol Assess Health Care 25:73-83. 2009
    ..We used CTA for the introduction of a new diagnostic test in the Netherlands, the 70-gene prognosis signature (MammaPrint) for node-negative breast cancer patients...
  11. doi request reprint Genomic profiling of histological special types of breast cancer
    Hugo M Horlings
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 142:257-69. 2013
    ....
  12. doi request reprint Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 71:1014-21. 2008
    ..5 years. In the present study, we evaluated the IBR incidence and the risk factors for IBR after prolonged follow-up...
  13. pmc Retrospective analysis of metastatic behaviour of breast cancer subtypes
    C Dilara Savci-Heijink
    Department of Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Breast Cancer Res Treat 150:547-57. 2015
    ..1 %. In metastatic breast cancer patients, tumour subtypes are associated with survival and pattern of distant metastases. These associations are of help in choices for surveillance and therapy in individual patients...
  14. doi request reprint HER2 gene amplification in patients with breast cancer with equivocal IHC results
    Sybren L Meijer
    Departments of Pathology of the Academic Medical Center, Amsterdam, The Netherlands
    J Clin Pathol 64:1069-72. 2011
    ....
  15. pmc EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
    Alexandra M Pietersen
    Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066X, The Netherlands
    Breast Cancer Res 10:R109. 2008
    ..This histone mark recruits the BMI1-containing PRC1 that silences the genes marked by PRC2. Based on their role in stem cells, EZH2 and BMI1 have been predicted to contribute to a poor outcome for cancer patients...
  16. doi request reprint Predictive factors for local recurrence in breast cancer
    Femke van der Leij
    The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Semin Radiat Oncol 22:100-7. 2012
    ..In this review, we describe the predictive and prognostic factors for local recurrence after mastectomy and BCT and also describe the role of radiosensitivity in local recurrence...
  17. ncbi request reprint Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer
    Ian F Faneyte
    Department of Experimental Therapy, Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Anticancer Res 24:2931-9. 2004
    ..Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated their role in breast cancer resistance to anthracycline-based chemotherapy...
  18. ncbi request reprint Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement
    Ian F Faneyte
    Department of Pathology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 10:4457-63. 2004
    ..There is limited knowledge of risk factors for breast cancer recurrence within 2 years. This study aimed to predict early failure and identify high-risk patients for prognostic and therapeutic purposes...
  19. pmc Receptor conversion in distant breast cancer metastases
    Laurien D C Hoefnagel
    Department of Pathology, University Medical Center Utrecht, The Netherlands
    Breast Cancer Res 12:R75. 2010
    ....
  20. ncbi request reprint Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas
    Els C Robanus-Maandag
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Pathol 201:75-82. 2003
    ..Thus, C-MYC amplification is the first identified genetic alteration that is associated with progression from the in situ to the invasive stage of breast carcinoma...
  21. pmc Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach
    Tim J A Dekker
    Department of Pathology, Academic Medical Center, Meibergdreef 9, Amsterdam, 1100 DD, The Netherlands
    Breast Cancer Res 14:R93. 2012
    ..False-positive rates of up to 20% for HER2 testing have been described. HER2-testing laboratories are therefore encouraged to participate in external quality control schemes in order to improve HER2-testing standardization...
  22. pmc Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials
    Jos A van der Hage
    Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res 13:R68. 2011
    ..The purpose of this study was to determine the prognostic value of established clinical and pathological prognostic factors in young breast cancer patients...
  23. ncbi request reprint Biological variables and prognosis of DCIS
    Marc J van de Vijver
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast 14:509-19. 2005
    ..Integration of translational studies into clinical trials aimed at optimising the treatment of DCIS are required to achieve this goal...
  24. pmc A novel gene expression signature for bone metastasis in breast carcinomas
    C Dilara Savci-Heijink
    Department of Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Breast Cancer Res Treat 156:249-59. 2016
    ..This bone metastasis signature is the first to be identified using a supervised classification approach in a large series of patients and will help forward research in this area towards clinical applications. ..
  25. doi request reprint First results of the preoperative accelerated partial breast irradiation (PAPBI) trial
    Femke van der Leij
    Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Radiother Oncol 114:322-7. 2015
    ..The aim of this study is to assess the toxicity and cosmetic outcome of preoperative accelerated partial breast irradiation (PAPBI) for breast cancer patients with low risk on local recurrence...
  26. ncbi request reprint [Breast lesion diagnosis: integrating pathology and radiology]
    Harmien M Zonderland
    Academisch Medisch Centrum, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 155:A2967. 2011
    ..Finally, in a 45-year old patient with a palpable mass, caused by a grade III ductal carcinoma in situ, successful excision with tumour-free margins was achieved thanks to preoperative MRI...
  27. ncbi request reprint Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer
    Anne Marie Cleton-Jansen
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Genes Chromosomes Cancer 41:109-16. 2004
    ..These different somatic genetic mechanisms may reflect the presence of multiple tumor suppressor genes that are the target of LOH at chromosome arm 16q...
  28. doi request reprint Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy
    Peter de Boer
    Department of Radiation Oncology, Academic Medical Centre AMC, University of Amsterdam UvA, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Eur J Radiol 82:e422-8. 2013
    ..Although MRI is generally considered the most reliable method, its value for detecting involvement of the uterine internal os is unclear...
  29. ncbi request reprint Technology Insight: tuning into the genetic orchestra using microarrays--limitations of DNA microarrays in clinical practice
    Ambreen Abdullah-Sayani
    Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Clin Pract Oncol 3:501-16. 2006
    ..This Review focuses on the limitations of microarray analysis that are continuously being recognized, and discusses how these limitations are being addressed...
  30. ncbi request reprint A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient
    Anne Marie Cleton-Jansen
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Lab Invest 84:191-202. 2004
    ..These distinct phenotypic findings support the existence of a new hitherto unrecognized syndrome, characterized by an increased risk to develop both breast cancer and centrally originating cartilaginous tumors...
  31. doi request reprint Translating the genomic architecture of breast cancer into clinical applications
    Hugo M Horlings
    Academic Medical Center, Department of Pathology, Meibergdreef 9, 1105AZ Amsterdam, Netherlands
    Sci Transl Med 2:38ps32. 2010
    ....
  32. doi request reprint Evolution of Screen-Detected Small (6-9 mm) Polyps After a 3-Year Surveillance Interval: Assessment of Growth With CT Colonography Compared With Histopathology
    Charlotte J Tutein Nolthenius
    Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am J Gastroenterol 110:1682-90. 2015
    ..We examined whether is it possible to predict which small (6-9 mm) polyps are likely to become advanced adenomas at surveillance by assessing volumetric growth...
  33. pmc A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer
    Fabien Reyal
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 10:R93. 2008
    ..we address the following issues: Do these signatures perform similarly? Are there (common) molecular processes reported by these signatures? Can better prognostic predictors be constructed based on these identified molecular processes?..
  34. pmc The diagnosis and management of pre-invasive breast disease: pathological diagnosis--problems with existing classifications
    Marc J van de Vijver
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res 5:269. 2003
    ..If there is doubt about the classification of an intraductal proliferation, a differential diagnosis and the reason for and degree of uncertainty should be given, rather than categorizing a proliferation as atypical...
  35. ncbi request reprint A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
    ..A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy...